Guideline for referral of patients with suspected lung cancer by family physicians and other primary care providers

M. Elisabeth Del Giudice MD MSc CCFP  Sheila-Mae Young MD  Emily T. Vella PhD  Marla Ash MD CCFP
Praveen Bansal MD CCFP FCPC  Andrew Robinson MD FRCP  Roland Skrastins MD FRCP  Yee Ung MD FRCP
Robert Zeldin MD FRCS FACS  Cheryl Levitt MB BCH CCFP FCFP

Abstract

Objective The aim of this guideline is to assist FPs and other primary care providers with recognizing features that should raise their suspicions about the presence of lung cancer in their patients.

Composition of the committee Committee members were selected from among the regional primary care leads from the Cancer Care Ontario Provincial Primary Care and Cancer Network and from among the members of the Cancer Care Ontario Lung Cancer Disease Site Group.

Methods This guideline was developed through systematic review of the evidence base, synthesis of the evidence, and formal external review involving Canadian stakeholders to validate the relevance of recommendations.

Report Evidence-based guidelines were developed to improve the management of patients presenting with clinical features of lung cancer within the Canadian context.

Conclusion Earlier identification and referral of patients with lung cancer might ultimately help improve lung cancer morbidity and mortality. These guidelines might also be of value for informing the development of lung cancer diagnostic programs and for helping policy makers to ensure appropriate resources are in place.

Lung cancer is the most common cause of cancer death in Canada.1 Lung cancers are frequently diagnosed at a late stage, and the prognosis is very poor.1 The chance of surviving lung cancer in Canada is low, with a 5-year survival rate of 13% for men and 19% for women.1 Delays in the diagnosis of lung cancer are well documented.2–11 This might in part be owing to patients and clinicians attributing the often common, atypical, or nonspecific symptoms of lung cancer to other, benign diseases.

In order to provide guidance for the introduction of lung cancer diagnostic assessment programs (DAPs) in Ontario, the Cancer Care Ontario (CCO) Provincial Primary Care and Cancer Network initiated a collaboration in October 2009 with CCO’s Program in Evidence-based Care (PEBC) to form the Lung Cancer Referral Working Group. The working group was tasked with providing recommendations that would help FPs and other primary care providers recognize and initiate the management of undiagnosed patients presenting with signs or symptoms of lung cancer. The following questions were evaluated in completing this overall objective.

• What main known risk factors are predictive of lung cancer?
• What signs, symptoms, and other clinical features are predictive of lung cancer?
The guideline was developed using the methods of the Patient, Radiation Oncology, Thoracic Surgeon, Respiratorist, Radiation Oncologist, Thoracic Surgeon, and Radiologist. The work of the PEBC is supported by the Ontario Ministry of Health and Long-Term Care through CCO, and the PEBC is editorially independent from its funding source.

Composition of committee
The working group consisted of 5 FPs (M.E.D., S.Y., M.A., P.B., C.L.), 1 medical oncologist (A.R.), 1 respiratorist (R.S.), 1 radiation oncologist (Y.U.), 1 thoracic surgeon (R.Z.), and 1 methodologist (E.T.V.). Committee members included regional primary care cancer leads selected from the Provincial Primary Care and Cancer Network and members of CCO’s Lung Cancer Disease Site Group. Internal and external reviewers included FPs, thoracic surgeons, and radiologists. The work of the PEBC is supported by the Ontario Ministry of Health and Long-Term Care through CCO, and the PEBC is editorially independent from its funding source.

Methods
The guideline was developed using the methods of the practice guideline development cycle, including an environmental scan of existing guidelines, systematic review of the evidence base, evidence synthesis, and input from internal and external reviewers across Canada. Further details of the methods and findings of the systematic review are published elsewhere.

Recommendations from the 2009 New Zealand Guidelines Group (NZGG),6 the 2004 Australian National Health and Medical Research Council,15 the 2005 National Institute for Health and Care Excellence (NICE),2 the American College of Chest Physicians’ evidence-based clinical practice guidelines,10,16,17 and the 2005 Scottish Intercollegiate Guidelines Network18 were considered during the guideline adaptation process. Updated evidence from primary studies was also taken into consideration. Many of the specific recommendations from the NZGG 2009 or NICE 2005 guidelines were endorsed or adapted. The following recommendations reflect the integration of the NZGG 2009 and NICE 2005 recommendations with evidence from level I systematic reviews, level II case-control and cohort studies, and level III expert opinion of the PEBC Lung Cancer Referral Working Group as described below.

The working group held teleconferences to develop and approve the recommendations through informal consensus. Each recommendation took into consideration evidence from the systematic review. Recommended wait times were based on expert opinion and consensus of the working group that often reflected feasibility in the Canadian health care system. Some members of the working group were part of a Canadian study (Lung Cancer Time to Treat Study), which showed wait times for specialist consultation among patients presenting with signs or symptoms causing suspicion of lung cancer can be reduced from 20 days to 6 days with the implementation of a DAP.

Report
The lung cancer guideline recommendations are presented in Figure 1 and are outlined below.

Factors that increase the risk of lung cancer. The risk factors for lung cancer provided in Box 1 were based on the summary of the NICE 2005 literature review provided by NZGG 2009. Our updated literature review did not provide evidence for additional risk factors associated with lung cancer beyond those listed in the NICE 2005 or NZGG 2009 guidelines.

Indications and recommended initial investigation for suspicious lung cancer. An urgent chest x-ray scan within 48 hours is recommended for all signs and symptoms causing suspicion of lung cancer. The working group adapted the NZGG 2009 guideline indications for urgent chest x-ray scan (Box 2). Modifications of the NZGG 2009 recommendations included removal of the 3-week time frame for new finger clubbing, suspicious lymphadenopathy, or presentation with clinical features suggestive of cancer metastasis to or from the lung. Dysphagia was added as an indication for chest x-ray scan because it was reported in the NICE 2005 review as a symptom of lung cancer and was found to be a main clinical symptom among lung cancer patients in a tertiary care setting. Furthermore, paraneoplastic syndromes were also included based on findings of a 2007 review by Spiro et al, who reportedly observed paraneoplastic syndromes in approximately 10% of patients presenting with lung cancer. For patients with underlying chronic respiratory problems, the working group chose to endorse the recommendation from NICE 2005, which recommended a chest x-ray scan for unexplained changes in existing symptoms lasting more than 3 weeks.

The recommendation for a 6-week follow-up of a consolidation found on a chest x-ray scan was adapted by the working group with modifications from the NZGG 2009 referral guideline. This recommendation was modified to include unexplained pleural effusion and to include all patients regardless of lung cancer risk factors (Box 2).
Figure 1. Lung cancer guideline recommendations

Does the patient have any of the following signs or symptoms?

- Persistent hemoptysis
- Signs of superior vena cava obstruction
- Stridor
- Massive hemoptysis (> 600 mL of blood in 24 h or a cup full [250 mL] at once)
- New neurological signs suggestive of brain metastases or cord compression

Yes

Refer to emergency department

No

- Hemoptysis
- New finger clubbing
- Suspicious lymphadenopathy
- Dysphagia
- Features suggestive of lung cancer that has metastasized elsewhere or other cancers that have metastasized to the lung
- Features suggestive of paraneoplastic syndromes

OR any of the following unexplained signs or symptoms lasting more than 3 wk (patients with known risk factors* might be considered sooner):

- Cough
- Weight loss or loss of appetite
- Shortness of breath
- Chest or shoulder pain
- Abnormal chest signs
- Hoarseness

Unexplained changes in existing symptoms in patients with underlying chronic respiratory problems

Performed within 3 wk

Chest x-ray scan

Read within 1 wk

Abnormal findings

Consolidation or unexplained pleural effusion

Repeat chest x-ray scan within 6 wk to confirm resolution

Chest x-ray film suggestive of or suspicious for lung cancer including

- A nodule or mass
- Multiple pulmonary nodules
- Nonresolving pleural effusion
- Mediastinal or contralateral hilar adenopathy
- Interstitial infiltrates
- Slowly or nonresolving pneumonia or consolidation
- Fibroapical disease suggesting possible tuberculosis
- Unexplained elevated diaphragm

Specialist referral and computed tomography scan

Referred and seen within 1-2 wk

High suspicion of lung cancer

Observe and manage

Normal findings

Performed within 2 working d

Within 1-2 wk

Risk factors include being a current or previous smoker, exposure to second-hand smoke, history of chronic obstructive pulmonary disease, previous exposure to asbestos or other known carcinogens, occupational exposure to dust or microscopic particles, personal or family history of cancer (especially lung, head, and neck cancer), silicosis, and tuberculosis.
There was considerable variability among guidelines regarding the indication for sputum cytology when lung cancer is suspected. The NICE 2005 and NZGG 2009 guidelines did not recommend sputum cytology. Because our updated literature search continued to find high specificity but variable sensitivity of sputum cytology in detecting lung cancer, the working group endorsed the NZGG 2009 recommendation against sputum cytology.

The NICE 2005 and NZGG 2009 guidelines did not provide reviews of or recommendations on the use of thoracic computed tomography (CT) scans in patients with suspected lung cancer. The updated literature search revealed a paucity of further studies. The working group developed indications for CT thoracic scan based on recommendations provided by the Scottish Intercollegiate Guidelines Network in 2005 and on the expert opinion of the working group members, especially from their experience with the Time to Treat program.

A recommendation for follow-up of solitary pulmonary nodules on imaging tests was adapted initially from the American College of Chest Physicians’ clinical practice guidelines for pulmonary nodules. However, after internal review, the working group chose to remove this recommendation because a patient with a solitary pulmonary nodule, independent of size, should be referred to a specialist.

**Indications and recommended referral for suspected lung cancer.** Indications for immediate referral to the emergency department were adapted from the NICE 2005 guidelines. Massive hemoptysis (defined as more than 600 mL of blood over 24 hours or more than 250 mL at once) and new neurologic signs suggestive of brain metastases or cord compression were added based on the expert opinion and consensus of the working group.

The indications for referral to a specialist were adapted by the working group from the NZGG 2009 and NICE 2005 referral guidelines. An unexplained elevated diaphragm was included, as per the suggestion of an internal reviewer. Additional suspicious abnormal chest x-ray scan findings and practice tips for specialist referral were based on the expert opinion of the working group members, especially from their experience with the Time to Treat program.
Owing to high false-negative results with chest x-ray scans, NICE 2005 and NZGG 2009 guidelines recommended referral to a specialist if there was a high suspicion of lung cancer despite normal chest x-ray scan findings. Two systematic reviews in our updated search also reported high false-negative results with chest x-ray scans. Thus, the recommendation urging clinicians to refer to a specialist if there is still a high suspicion of lung cancer was endorsed.

**Recommendations to reduce diagnostic delay.** The recommendations to reduce diagnostic delay were taken from evidence found in the NZGG 2009 and NICE 2005 guidelines, as well as from the updated literature search (Box 5). The patient- or FP-related factors that might delay referral or the diagnosis of lung cancer included fear of a diagnosis of cancer, not recognizing the signs and symptoms suggestive of lung cancer, comorbidities, multiple consecutive investigations in primary care, overreliance on chest x-ray scan results to diagnose lung cancer, failure to follow up on imaging results, and initial referral to a non-respiratory physician.

**Box 3. Indications for referral of suspicious lung cancer**

**Indications for referral to the ED**

Patients should be referred to the ED if they have any of the following:

- Signs of superior vena cava obstruction
- Stridor
- Massive hemoptysis
- New neurologic signs suggestive of brain metastases or cord compression
- Persistent hemoptysis
- Chest x-ray film findings suggestive of or suspicious for lung cancer including- a nodule or mass,
- multiple pulmonary nodules,
- nonresolving pleural effusion,
- mediastinal or contralateral hilar adenopathy,
- interstitial infiltrates,
- slowly resolving or nonresolving pneumonia or consolidation,
- fibropapilial disease suggesting possible tuberculosis, or
- unexplained elevated diaphragm

**Indications for referral to a specialist (respirologist or thoracic surgeon) or DAP**

Patients should be referred to and expect a consultation with a specialist or, where locally available, to a DAP within 1 to 2 weeks if they have any of the following:

- Persistent hemoptysis
- Chest x-ray film findings suggestive of or suspicious for lung cancer including
  - a nodule or mass,
  - multiple pulmonary nodules,
  - nonresolving pleural effusion,
  - mediastinal or contralateral hilar adenopathy,
  - interstitial infiltrates,
  - slowly resolving or nonresolving pneumonia or consolidation,
  - fibropapilial disease suggesting possible tuberculosis, or
  - unexplained elevated diaphragm
- Normal chest x-ray findings but there is a high suspicion of lung cancer based on clinical judgment

If promptly accessible, a chest CT scan can be simultaneously ordered with the referral while awaiting the specialist’s consultation. This will depend on locally available resources. If the CT scan findings are entirely negative, then further referral to a specialist can be cancelled.

**Box 4. Practice tips for investigations and referral of patients with suspected lung cancer**

The requisition for a chest x-ray scan should include the presenting history, including signs and symptoms causing suspicion of lung cancer and whether risk factors (Box 1) exist

- Within 1 week of being ordered, chest x-ray scans should be completed, reviewed, and reported on by the radiologist, and the report should be read by the ordering physician
- If the chest x-ray findings raise suspicion of lung cancer, an alternate mechanism of informing the ordering physician should occur (eg, telephone call, flagging)

To expedite the diagnosis and avoid duplication of investigations, at a minimum provide the specialist consultant with the following information:

- Patient’s history, including all risk factors and signs or symptoms causing suspicion of lung cancer
- All pre-existing imaging results (all efforts should be made to provide these), including chest x-ray and CT scans (films and digital images should be available at the time of consultation)
- All other relevant medical conditions and medications taken by the patient
- All recent bloodwork results

CT—computed tomography. DAP—diagnostic assessment program, ED—emergency department.
Box 5. Recommendations to reduce diagnostic delay

The following could contribute to reducing diagnostic delay:

- There should be appropriate educational tools developed and disseminated that highlight the signs and symptoms of lung cancer for clinicians and for patients.
- Clinicians should have a high index of suspicion with a low threshold for investigation of suspected lung cancer in ordering chest x-ray scans and referring patients to lung cancer specialists or diagnostic assessment programs.
- Decision-support tools should be readily available to assist clinicians.
- Clinicians should include as much information as possible in their referral letters and should ask patients to help retrieve electronic copies of their imaging tests to bring to specialist appointments.
- Counseling of patients should occur to address common fears and concerns.
- Public health and other health agencies should work with local community leaders to address challenges, such as lower levels of education or demographic discrepancies in communities with high rates of lung cancer or known delays in lung cancer diagnosis.

Data from the National Institute for Health and Care Excellence, the New Zealand Guidelines Group, and Spiro et al.

Cancer care based on chest x-ray film findings or clinical judgment (despite negative chest x-ray film findings), and depending on locally available resources, a chest CT scan and referral to a respirologist or thoracic surgeon are recommended.

While there is no published evidence on the effects of wait times on patient outcomes, it is generally believed that earlier diagnosis of lung cancer would likely lead to improved prognosis. Delays in diagnosis might be avoided if clinicians have a low threshold for ordering chest x-ray scans for patients presenting with even vague symptoms of lung cancer. If warranted, an expedited referral to a specialist or a DAP for further investigation should also be made. Attempts to address delays in diagnosis should be made at the patient, provider, and policy levels.

This guideline could help reduce delays in lung cancer diagnosis by assisting FPs and other primary care providers in recognizing clinical features that should raise their suspicion about the presence of lung cancer and lead them to make more timely and appropriate referrals. It might also guide program development of DAs for patients with suspected lung cancer and help policy makers to ensure that resources are in place so that target wait times can be achieved.

Dr Del Giudice is a physician with the Sunnybrook Academic Family Health Team in Toronto, Ont, and is Regional Primary Care Cancer Lead for the Toronto Central Local Health Integration Network. Dr Young is a family physician in Lindsay, Ont. Dr Vella is Health Research Methodologist in the Department of Oncology at McMaster University in Hamilton, Ont, and for Cancer Care Ontario’s Program in Evidence-based Care. Dr Ash is a family physician with the North York Family Health Team in Ontario. Dr Bansal is a family physician in Brampton, Ont. Dr Robinson is Assistant Professor in the Department of Oncology at Queen’s University in Kingston, Ont. Dr Skrastins is a respiratory physician in Toronto, Ont. Dr Ung is Associate Professor in the Department of Radiation Oncology at the University of Toronto and a staff radiation oncologist at Sunnybrook Odette Cancer Centre. Dr Zeldin is Associate Physician in the Division of Thoracic Surgery at the University of Toronto and Medical Director of Surgical Oncology at the Toronto East General Hospital. Dr Levitt is Professor in the Department of Family Medicine at McMaster University and Past Provincial Primary Care Lead at Cancer Care Ontario.

Contributors
All authors contributed to the literature review and interpretation, and to preparing the report for submission.

Competing interests
None declared.

Correspondence
Dr M. Elisabeth Del Giudice c/o Dr Emily T. Vella, McMaster University, Oncology, 711 Concession St, Hamilton, ON L8V 1C3, e-mail ccopgi@mcmaster.ca

References